Protein profiling of downstream targets of β-catenin. (A,B) MM.1S cells were exposed to enzastaurin with increasing concentrations (A) or time periods (B), followed by immunoblotting with the indicated antibodies. (C) Primary MM patient cells were exposed to enzastaurin and immunoblotted as indicated. (D) Indicated cells were treated with enzastaurin or BIM I (both 5 μM, 24 hours), followed by immunoblotting with indicated antibodies. C indicates control; E, enzastaurin; B, BIM I.